• 1
    Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 8795.
  • 2
    Hasse B, Ledergerber B, Furrer H et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 11301139.
  • 3
    D:A:D Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 4
    Marin B, Thiébaut R, Bucher HC et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 17431753.
  • 5
    The Strategies for management of antiretroviral therapy (SMART) Study Group. N Engl J Med 2006; 355: 22832296.
  • 6
    Klein D, Leyden WA, Xu L et al. Contribution of immunodeficiency to coronary heart disease: cohort study of HIV-infected and HIV-uninfected Kaiser Permanente members. Poster presented at the 18th Conference on Retroviruses and Opportunistic Infections (2011). Available at: (accessed 22 June 2012).
  • 7
    Lodwick RK, Sabin CA, Porter K et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376: 340345.
  • 8
    Zwahlen M, Harris R, May M et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 16241633.
  • 9
    Nakagawa F, Lodwick RK, Smith CJ et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335343.
  • 10
    Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829841.
  • 11
    Aboud M, Elgalib A, Pomeroy L et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract 2010; 64: 12521259.
  • 12
    Obel N, Omland LH, Kronborg G et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS ONE 2011; 6: e22698.
  • 13
    World Health Organization. Global status report on noncommunicable diseases 2010. WHO, Geneva, 2011, ISBN 978 92 4 156422 9.
  • 14
    Department of Health. Vascular Programme. Putting prevention first – vascular checks: risk assessment and management. London, UK. Department of Health. 2008; Report no. 287093.
  • 15
    Roglic G, Unwin N, Bennett PH et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 21302135.
  • 16
    Yorkshire and Humber Public Health Authority (2008). Diabetes attributable deaths: estimating the excess deaths among people with diabetes. Available at: (accessed 22 June 2012).
  • 17
    Freedman BI, Hicks PJ, Bostrom MA et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736745.
  • 18
    Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42: 677684.
  • 19
    Catapano AL, Reiner Z, De Backer G et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 346.
  • 20
    Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 14751482.
  • 21
    National Institute for Health and Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Clinical guideline CG67. May 2008. London, UK.
  • 22
    Department of Health. NHS Health Check Programme. Putting prevention first – NHS health check: vascular risk assessment and management best practice guidance. London, UK. Department of Health. 2009. Report no. 11473.
  • 23
    Kanis JA, Johnell O, Oden A et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International 2008; 19: 385397.
  • 24
    Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis. Guideline No. 71. June 2003 (updated April 2004). Available at: (accessed 22 June 2012).
  • 25
    International Osteoporosis Foundation. Available at: (accessed 22 June 2012).
  • 26
    Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407413.
  • 27
    Asboe D, Aitken C, Boffito M et al., BHIVA Guidelines Subcommittee. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals. HIV Med 2012; 13: 144.
  • 28
    European AIDS Clinical Society (EACS). Guidelines. Part III. Prevention and management of non-infectious co-morbidities in HIV. Version 6.1 – November 2011. Available at (accessed 22 June 2012).
  • 29
    Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6: 266271.
  • 30
    Grunfeld C, Delaney JA, Wanke C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23: 18411849.
  • 31
    Kuller LH, Tracy R, Belloso W et al., INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
  • 32
    Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 20932099.
  • 33
    Holmberg SD, Moorman AC, Williamson JM et al., HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 34
    Mary-Krause M, Cotte L, Simon A et al; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 35
    D:A:D Study Group, Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 17231735.
  • 36
    D:A:D Study Group, Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 14171426.
  • 37
    Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318330.
  • 38
    Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:12281238.
  • 39
    Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218230.
  • 40
    Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH et al. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64: 739745.
  • 41
    Guaraldi G, Orlando G, Squillace N et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006; 7: 97106.
  • 42
    Butt AA, Fultz SL, Kwoh CK et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004; 40: 115119.
  • 43
    Butt AA, McGinnis K, Rodriguez-Barradas MC et al., Veterans Aging Cohort Study. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 12271234.
  • 44
    De Wit S, Sabin CA, Weber R et al., Data collection on adverse events of anti-HIV drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2008; 31: 12241229.
  • 45
    National Institute for Health and Clinical Excellence. Type 2 diabetes. The management of type 2 diabetes (update). Clinical guideline CG66. December 2008. London, UK.
  • 46
    Hippisley-Cox J, Coupland C, Robson J et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QD Score. BMJ 2009; 338: b880.
  • 47
    Longenecker CT, Scherzer R, Bacchetti P et al. HIV viremia and changes in kidney function. AIDS 2009; 23: 10891096.
  • 48
    Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis 2009; 22: 4348.
  • 49
    Winston J, Deray G, Hawkins T et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008; 47: 14491457.
  • 50
    Campbell LJ, Ibrahim F, Fisher M et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Medicine 2009; 10: 329336.
  • 51
    Adih WK, Selik RM, Hu X. Trends in diseases reported on US death certificates that mentioned HIV infection, 1996–2006. J Int Assoc Physicians AIDS Care (Chic) 2011; 10: 511.
  • 52
    Data collection on adverse events of anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 15371548.
  • 53
    Mocroft A, Kirk O, Reiss P et al., EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 16671678.
  • 54
    Arnsten JH, Freeman R, Howard AA et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617623.
  • 55
    Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 21652174.
  • 56
    Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS 2012; 26: 253262.
  • 57
    Brown TT, McComsey GA, King MS et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554561.
  • 58
    Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab 2008; 93: 34993504.
  • 59
    Womack JA, Goulet JL, Gibert C et al., Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6: e17217.
  • 60
    Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648654.
  • 61
    Gray NJ, Klein JD, Noyce PR et al. Health information-seeking behaviour in adolescence: the place of the internet. Soc Sci Med 2005; 60: 14671478.
  • 62
    Bass SB, Ruzek SB, Gordon TF et al. Relationship of internet health information use with patient behavior and self-efficacy: experiences of newly diagnosed cancer patients who contact the National Cancer Institute's Cancer Information Service. J Health Commun 2006; 11: 219236.
  • 63
    Sharp J. The internet. Changing the way cancer survivors receive support. Cancer Pract 2000; 8: 145147.
  • 64
    Fleisher L, Bass S, Ruzek SB, McKeown-Conn N. Relationships among internet health information use, patient behavior and self efficacy in newly diagnosed cancer patients who contact the National Cancer Institute's NCI Atlantic Region Cancer Information Service (CIS). Proc AMIA Symp 2002:260264.
  • 65
    Christakis NA. Social networks and collateral health effects. BMJ 2004; 329: 184185.
  • 66
    Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med 2007; 357: 370379.
  • 67
    Chou WY, Hunt YM, Beckjord EB et al. Social media use in the United States: implications for health communication. J Med Internet Res 2009; 11: e48.
  • 68
    Facebook statistics, December 2011. Available at (accessed 22 December 2011).
  • 69
    Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: Twitter and antibiotics. Am J Infect Control 2010; 38: 182188.
  • 70
    Farmer AD, Bruckner Holt CE, Cook MJ, Hearing SD. Social networking sites: a novel portal for communication. Postgrad Med J 2009; 85: 455459.